p97

信号通路图

研究领域

抑制剂选择性比较

p97产品

所有产品 p97抑制剂(4)

目录号	产品描述	文献引用	实验数据
S7285	NMS-873 NMS-873是特异性p97的变构抑制剂，IC50=30nM，对VCP/p97的选择性相对于对其他AAA ATPase、Hsp90和其他所检测激酶较高。	Nature, 2020, 578(7794):296-300 Nature, 2020, 578(7794):296-300 Cell Rep, 2020, 30(6):1835-1847	(E) The mDPC level induced by HN2 in the presence of MG132 or NMS-873. MG132 or NMS-873 were added for 3 h after HN2 exposure and then replaced by normal medium until 24 h.
S7199	DBeQ DBeQ是一种选择性的，有效的，可逆的，ATP竞争性的p97抑制剂，IC50为1.5 μM。	Cell, 2019, 177(3):766-781 EMBO J, 2019, 38(21):e102361 Leukemia, 2019, 10.1038/s41375-018-0355-y
S4921	MNS (3,4-Methylenedioxy-β-nitrostyrene) MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)是一种酪氨酸激酶抑制剂，抑制Syk， Src和p97， IC50分别为2.5 μM， 29.3 μM和1.7 μM。	J Biomol Struct Dyn, 2019, 10.1080/07391102.2019.1640133 Toxicol Res (Camb), 2016, 5(1):188-196	WT mouse primary macrophages were untreated as control (lane 1) or treated with 0.1μg/ml E. coli LPS (lane 5-8), 10μM E-64 (lane 2 and 6), 250μM PMSF (lane 3 and 7), or 20μM MNS (lane 4 and 8). The cells were continuously cultured for 16 hrs. Extracts from whole cells or nuclei were separately purified and subjected to WB analysis with antibody against pERK2, LITAF, or actin/tubulin as control.
S8101	CB-5083 CB-5083是一种有效的，选择性的，且口服具有生物活性的p97 AAA ATPase抑制剂，IC50为 11 nM。Phase 1。	Cells, 2020, 9(2) Cell Cycle, 2020, 19;1-12 Cell, 2019, 177(3):766-781	LN229 GBM cell lysates were immunoblotted with antibodies recognizing specific focal adhesion proteins. Note the decreased levels of Cas, paxillin, and FAK tyrosine phosphorylation in cells treated with CB-5083. In addition, CB-5083 treatment leads to decreased levels of total PTP-PEST expression, but Vcp protein expression levels are not impacted.

目录号	产品描述	文献引用	实验数据
S7285	NMS-873 NMS-873是特异性p97的变构抑制剂，IC50=30nM，对VCP/p97的选择性相对于对其他AAA ATPase、Hsp90和其他所检测激酶较高。	Nature,2020, 578(7794):296-300 Nature,2020, 578(7794):296-300 Cell Rep,2020, 30(6):1835-1847	(E) The mDPC level induced by HN2 in the presence of MG132 or NMS-873. MG132 or NMS-873 were added for 3 h after HN2 exposure and then replaced by normal medium until 24 h.
S7199	DBeQ DBeQ是一种选择性的，有效的，可逆的，ATP竞争性的p97抑制剂，IC50为1.5 μM。	Cell,2019, 177(3):766-781 EMBO J,2019, 38(21):e102361 Leukemia,2019, 10.1038/s41375-018-0355-y
S4921	MNS (3,4-Methylenedioxy-β-nitrostyrene) MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)是一种酪氨酸激酶抑制剂，抑制Syk， Src和p97， IC50分别为2.5 μM， 29.3 μM和1.7 μM。	J Biomol Struct Dyn,2019, 10.1080/07391102.2019.1640133 Toxicol Res (Camb),2016, 5(1):188-196	WT mouse primary macrophages were untreated as control (lane 1) or treated with 0.1μg/ml E. coli LPS (lane 5-8), 10μM E-64 (lane 2 and 6), 250μM PMSF (lane 3 and 7), or 20μM MNS (lane 4 and 8). The cells were continuously cultured for 16 hrs. Extracts from whole cells or nuclei were separately purified and subjected to WB analysis with antibody against pERK2, LITAF, or actin/tubulin as control.
S8101	CB-5083 CB-5083是一种有效的，选择性的，且口服具有生物活性的p97 AAA ATPase抑制剂，IC50为 11 nM。Phase 1。	Cells,2020, 9(2) Cell Cycle,2020, 19;1-12 Cell,2019, 177(3):766-781	LN229 GBM cell lysates were immunoblotted with antibodies recognizing specific focal adhesion proteins. Note the decreased levels of Cas, paxillin, and FAK tyrosine phosphorylation in cells treated with CB-5083. In addition, CB-5083 treatment leads to decreased levels of total PTP-PEST expression, but Vcp protein expression levels are not impacted.